These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 30096175)
1. Contribution of excision repair cross-complementing group 1 genotypes to triple negative breast cancer risk. Tsai CW; Chang WS; Shen TC; Su CH; Wang HC; Liu LC; Bau DT PLoS One; 2018; 13(8):e0202112. PubMed ID: 30096175 [TBL] [Abstract][Full Text] [Related]
2. The Contribution of Excision Repair Cross-complementing Group 1 Genotypes to Colorectal Cancer Susceptibility in Taiwan. Yueh TC; Chou AK; Gong CL; Fu CK; Pei JS; Wu MH; Tsai CW; Chang WS; Hsiao CL; Yen ST; Li HT; Bau DT Anticancer Res; 2017 May; 37(5):2307-2313. PubMed ID: 28476796 [TBL] [Abstract][Full Text] [Related]
3. The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk. Chen LH; Shen TC; Li CH; Chiu KL; Hsiau YC; Wang YC; Gong CL; Wang ZH; Chang WS; Tsai CW; Hsia TC; Bau DT Cancer Genomics Proteomics; 2020; 17(5):571-577. PubMed ID: 32859635 [TBL] [Abstract][Full Text] [Related]
4. Association of Khalouei A; Masoumi-Ardakani Y; Jafarzaheh A; Kalantari Khandani B; Sedghy F; Khosravi Mashizi A; Yaghoobi MM; Zangouey M; Shahouzehi B J Res Health Sci; 2024 Sep; 24(4):e00631. PubMed ID: 39431656 [TBL] [Abstract][Full Text] [Related]
5. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy]. Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563 [TBL] [Abstract][Full Text] [Related]
6. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort. Bao Y; Yang B; Zhao J; Shen S; Gao J Int J Immunogenet; 2020 Oct; 47(5):443-453. PubMed ID: 32173978 [TBL] [Abstract][Full Text] [Related]
7. Contribution of DNA Double-strand Break Repair Gene XRCC3 Genotypes to Triple-negative Breast Cancer Risk. Su CH; Chang WS; Hu PS; Hsiao CL; Ji HX; Liao CH; Yueh TC; Chuang CL; Tsai CW; Hsu CM; Lane HY; Bau DT Cancer Genomics Proteomics; 2015; 12(6):359-67. PubMed ID: 26543082 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of ERCC1 and ERCC2 gene polymorphisms in patients with gastric cancer receiving platinum-based chemotherapy. Mo J; Luo M; Cui J; Zhou S Int J Clin Exp Pathol; 2015; 8(11):15065-71. PubMed ID: 26823845 [TBL] [Abstract][Full Text] [Related]
9. Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies. Ding YW; Gao X; Ye DX; Liu W; Wu L; Sun HY Clin Transl Oncol; 2015 Sep; 17(9):710-9. PubMed ID: 26022132 [TBL] [Abstract][Full Text] [Related]
10. Effect of ERCC1 polymorphism on the response to chemotherapy and clinical outcome of non-small cell lung cancer. Gao H; Ge RC; Liu HY; Wang Y; Yan S Genet Mol Res; 2014 Oct; 13(4):8997-9004. PubMed ID: 25366790 [TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in the ERCC1 and XPF genes and risk of breast cancer in a Chinese population. Yang Z; Fang X; Pei X; Li H Genet Test Mol Biomarkers; 2013 Sep; 17(9):700-6. PubMed ID: 23909490 [TBL] [Abstract][Full Text] [Related]
12. Study on the ERCC1 gene polymorphism response to chemotherapy and prognosis of gastric cancer. Liu L; Li CH; Jin TF; Xu DY Genet Mol Res; 2014 Oct; 13(4):8722-8. PubMed ID: 25366763 [TBL] [Abstract][Full Text] [Related]
13. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients. Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176 [TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma. Sun Y; Wu Y; Li W; Kong Z; Zou X Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355 [TBL] [Abstract][Full Text] [Related]
15. DNA repair genes XRCC1 and ERCC1 polymorphisms and the risk of sporadic breast cancer in Han women in the Gansu Province of China. Zhu G; Wang L; Guo H; Lu L; Yang S; Wang T; Guo H; Wang H; Min J; Yang K; Chen X; Liu Y; Wang Z; Su H Genet Test Mol Biomarkers; 2015 Jul; 19(7):387-93. PubMed ID: 25961110 [TBL] [Abstract][Full Text] [Related]
16. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer. Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265 [TBL] [Abstract][Full Text] [Related]
17. Genetic variability of DNA repair mechanisms influences chemotherapy outcome of gastric cancer. Yu H; Wu X; Zhang Y; Jin Z; Li G; Zhao H Int J Clin Exp Pathol; 2015; 8(4):4106-12. PubMed ID: 26097599 [TBL] [Abstract][Full Text] [Related]
18. The determination of relationship between "excision repair cross-complementing group 1" (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer. Koç E; Caner V; Büyükpınarbaşılı N; Tepeli E; Türk NS; Ozan Çetin G; Bağcı G Mol Biol Rep; 2012 Jan; 39(1):375-80. PubMed ID: 21553053 [TBL] [Abstract][Full Text] [Related]
19. Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Lu ZM; Luo TH; Nie MM; Fang GE; Ma LY; Xue XC; Wei G; Ke CW; Bi JW Tumour Biol; 2014 Apr; 35(4):2941-8. PubMed ID: 24318989 [TBL] [Abstract][Full Text] [Related]